Statera Biopharma EBITDA

What does Statera Biopharma do? Statera Biopharma develops immunotherapies targeting autoimmune diseases, neutropenia/anemia, emerging viruses, and cancers using a proprietary platform that rebalances the immune system. The company focuses on TLR agonists and antagonists, including Entolimod and GP532, with clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205). Statera generates revenue through clinical development and potential future product sales, targeting healthcare providers and pharmaceutical partners for its therapies. The company’s primary segments are autoimmune therapies, oncology, and infectious disease treatments, with Entolimod serving as a key product in hematology and immune modulation. Statera Biopharma’s business model relies on advancing its clinical-stage therapies through partnerships and licensing deals, with Entolimod and STAT-201 as flagship programs. The company’s TLR platform enables targeted immune responses, attracting interest from biopharmaceutical firms seeking innovative treatments. Revenue streams include milestone payments from collaborators and potential royalties on future commercialized products, focusing on segments such as autoimmune disorders, cancer, and viral infections. The firm’s development pipeline includes STAT-401 for pancreatic cancer and STAT-205 for COVID-19, positioning it for growth in high-demand therapeutic areas. The company’s products Entolimod and GP532 are central to its strategy, with Entolimod targeting hematology and immune-related conditions. Clinical programs like STAT-201 for Crohn’s disease and STAT-401 for pancreatic cancer represent key revenue opportunities. Statera Biopharma’s target customers include hospitals, clinics, and pharmaceutical companies, with a focus on delivering therapies for autoimmune, inflammatory, and cancer-related conditions. The business model emphasizes clinical progress to secure partnerships and generate future sales in the biopharmaceutical market. Statera Biopharma is one of the most popular companies on Eulerpool.